Journal of Clinical Psychopharmacology
LightNews LightNews
psychopharm.bsky.social
Journal of Clinical Psychopharmacology
@psychopharm.bsky.social
33 followers 51 following 59 posts
Journal of Clinical Psychopharmacology keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents.

Website: http://www.psychopharmacology.com
Podcast: https://jcpjournal.libsyn.com
Posts Replies Media Videos
psychopharm.bsky.social
A new analysis of over 17,000 #clozapine-related #fatalities shows that young and middle-aged females face a notably higher risk of fatal #pulmonary #embolism, while #pneumonia remains the leading fatal outcome in older adults.

🔗Read more in our current issue: journals.lww.com/psychopharma...
November 21, 2025 at 6:11 PM
psychopharm.bsky.social
Journal of Clinical Psychopharmacology is still accepting applications for its inaugural Editorial Fellowship Program. This two-year, paid fellowship offers hands-on experience in academic publishing and psychiatric research. Learn more below and apply today!
November 20, 2025 at 8:33 PM
psychopharm.bsky.social
Ketogenic diets are gaining attention as a potential adjunctive treatment for bipolar disorder, but how do they interact with modern psychotropic regimens? @mayoclinic.org experts discuss this topic in our new podcast episode.

🎧 podcasts.apple.com/us/podcast/d...
📰 journals.lww.com/psychopharma...
November 18, 2025 at 8:25 PM
psychopharm.bsky.social
We honor the life and legacy of Dr. Max Fink (1923–2025), a visionary in ECT, catatonia, and clinical psychopharmacology, and a longtime supporter of our journal. His legacy of scholarship and mentorship continues to inspire.
🕯️
journals.lww.com/psychopharma...
journals.lww.com
November 13, 2025 at 8:08 PM
psychopharm.bsky.social
In a new JCP article and podcast episode, Drs. Nicolas Badre and Eric Geier present a practical #anticholinergic equivalence table to help clinicians assess and minimize psychotropic anticholinergic burden.

🎧 Podcast: podcasts.apple.com/us/podcast/a...
📰 Article: journals.lww.com/psychopharma...
November 12, 2025 at 3:24 PM
psychopharm.bsky.social
How should we balance evidence-based medicine with clinical experience in treating depression?

Our latest guest editorial challenges Kennedy et al.’s critique of the STAR*D trial, arguing that standard antidepressant RCTs miss real-world complexity.

🔗 Read more: journals.lww.com/psychopharma...
November 4, 2025 at 8:29 PM
psychopharm.bsky.social
A new review article in JCP challenges key STAR*D findings: Common depression treatment steps may not outperform placebo in blinded RCTs.

🔗 Read more in our current issue: journals.lww.com/psychopharma...

#psychopharmacology #depression #TRD #antidepressants #STARD #RCT
November 3, 2025 at 4:03 PM
psychopharm.bsky.social
Our November/December 2025 issue (Volume 45, issue 6) is now available online: journals.lww.com/psychopharma...

Brief synopsis of the new issue from the Journal of Clinical Psychopharmacology Editor-in-Chief is below.
October 30, 2025 at 9:31 PM
psychopharm.bsky.social
A 2025 Executive Order calls SSRIs a “threat” to youth. Our latest editorial and podcast revisit the evidence: #SSRIs remain safe, effective, and essential for many youth with anxiety, depression, & OCD.

🎧 Podcast: jcpjournal.libsyn.com/fact-versus-...
📰 Editorial: journals.lww.com/psychopharma...
October 28, 2025 at 4:48 PM
psychopharm.bsky.social
What is olfactory reference disorder, and how should it be treated? In our latest Ask the Experts, Dr. Katharine Phillips of @weillcornell.bsky.social discusses this underrecognized condition, defined by the persistent false belief of emitting a foul body odor.

🔗 journals.lww.com/psychopharma...
October 21, 2025 at 2:46 PM
psychopharm.bsky.social
While #aripiprazole is generally well tolerated, a new review in the Journal of Clinical Psychopharmacology highlights rare cases of #rhabdomyolysis, even at standard or low doses.

🔗Read more in our current issue: journals.lww.com/psychopharma...
October 20, 2025 at 3:37 PM
psychopharm.bsky.social
A newly published comprehensive systematic review in JCP analyzes all FDA-approved psychiatric medications for sleep-wake disorders from 2008 to 2024. The review details mechanisms of action, indications, efficacy, dosing, and adverse effects.

🔗Read more: journals.lww.com/psychopharma...
October 17, 2025 at 3:06 PM
psychopharm.bsky.social
Pathologic #laughter is rare and often treated with SSRIs. However, a new JCP case report describes it paradoxically triggered by #sertraline in a patient with depression and no neuro findings. A reminder to monitor for atypical SSRI effects.

🔗 Read more: journals.lww.com/psychopharma...
October 15, 2025 at 4:32 PM
psychopharm.bsky.social
We are pleased to announce an exciting opportunity for early-career researchers: JCP is now accepting applications for its inaugural Editorial Fellowship Program. This 2-year paid fellowship offers hands-on experience in academic publishing and psychiatric research. Learn more below and apply today!
October 14, 2025 at 2:29 PM
psychopharm.bsky.social
#Centanafadine, a potential first-in-class NDSRI, showed sustained symptom improvement and was well tolerated over 52 weeks in adults with #ADHD. No signs of abuse or withdrawal. A promising #nonstimulant option.

🔗 Read more in our current issue: journals.lww.com/psychopharma...
October 10, 2025 at 3:10 PM
psychopharm.bsky.social
A new study in JCP found that higher BMI was significantly associated with remission in patients on #clozapine, supporting the idea of a “metabolic threshold” for antipsychotic efficacy.

🔗 Read more in our current issue: journals.lww.com/psychopharma...
October 7, 2025 at 2:45 PM
psychopharm.bsky.social
Not all low moods are depression. In our latest editorial and podcast, the authors explore how states like demoralization and dispiritedness differ from MDD.

🎧 Podcast: jcpjournal.libsyn.com/variability-...
📰 Editorial: journals.lww.com/psychopharma...
October 3, 2025 at 2:55 PM
psychopharm.bsky.social
We are pleased to announce an exciting opportunity for early-career researchers: JCP is now accepting applications for its inaugural Editorial Fellowship Program. This 2-year paid fellowship offers hands-on experience in academic publishing and psychiatric research. Learn more below and apply today!
September 30, 2025 at 2:51 PM
psychopharm.bsky.social
A 2025 Executive Order calls SSRIs a “threat” to youth. Our latest editorial and podcast revisit the evidence: #SSRIs remain safe, effective, and essential for many youth with anxiety, depression, & OCD.

🎧 Podcast: jcpjournal.libsyn.com/fact-versus-...
📰 Editorial: journals.lww.com/psychopharma...
September 29, 2025 at 3:58 PM
psychopharm.bsky.social
Clozapine remains underutilized despite its efficacy in treatment-resistant #schizophrenia. In a new 12-year review published in our current issue, only 7.5% of #clozapine users discontinued due to serious side effects, most manageable with monitoring.

🔗 journals.lww.com/psychopharma...
September 24, 2025 at 5:45 PM
psychopharm.bsky.social
A first-in-human Phase 1 trial of #RE104, a short-acting #serotonergic #psychedelic prodrug, has just been published in JCP. In this placebo-controlled RCT, RE104 was safe and well-tolerated up to 30 mg, producing psychedelic effects that lasted about 3-4 hours.

🔗 journals.lww.com/psychopharma...
September 24, 2025 at 5:11 PM
psychopharm.bsky.social
📰 Read the article: journals.lww.com/psychopharma...
🎧 Listen to the podcast: jcpjournal.libsyn.com/how-does-pos...

medicine.yale.edu/news-article...
Yale Professor Publishes Landmark Study on Depression Treatment
Somaia Mohamed, MD, PhD, associate professor of psychiatry, is a co-author and a lead investigator of a groundbreaking secondary analysis of the VAST-D study,
medicine.yale.edu
September 15, 2025 at 7:56 PM
psychopharm.bsky.social
With recurring #lorazepam shortages, #midazolam may be a safe and effective alternative for #agitation. A new study shows that IM midazolam (combined with haloperidol and diphenhydramine) is similarly effective, with quicker recovery and less oversedation.

🔗 journals.lww.com/psychopharma...
September 12, 2025 at 1:43 PM
psychopharm.bsky.social
#Anhedonia - the inability to feel pleasure - is a core symptom of major depressive disorder and remains challenging to treat. The phase 2 #TERPSIS study evaluated NBI-1065846, a novel experimental #GPR139 #agonist targeting the #lateral #habenula.

🔗 Read more: journals.lww.com/psychopharma...
September 10, 2025 at 4:29 PM
psychopharm.bsky.social
Not all low moods are depression. In our latest editorial and podcast, the authors explore how states like demoralization and dispiritedness differ from MDD.

🎧 Podcast: jcpjournal.libsyn.com/variability-...
📰 Editorial: journals.lww.com/psychopharma...
September 9, 2025 at 4:32 PM